Insilico Medicine secures $500 million in Series C funding to advance AI-discovered drug candidates into clinical trials.
Insilico Medicine, a pioneer in AI-powered drug discovery, has raised $500 million in Series C funding to advance its pipeline of AI-discovered drug candidates into clinical trials. The round was led by Andreessen Horowitz with participation from existing investors.
The company's AI platform has already identified 12 novel drug candidates across oncology, immunology, and neurology, with two having entered Phase 1 clinical trials. The new funding will accelerate development of the remaining candidates and expand the platform's capabilities.
"Traditional drug discovery takes 5-7 years and billions of dollars. Our AI can identify promising compounds in 18 months for a fraction of the cost," said Insilico's founder and CEO. "This funding allows us to prove our approach at clinical scale."
Insilico's platform uses generative AI to design novel molecular structures, then simulates their properties and predicts efficacy. The company has partnerships with pharmaceutical giants including Pfizer, Bristol Myers Squibb, and Roche.
The funding round values Insilico at $3.5 billion, making it one of the most valuable AI drug discovery companies globally.
